Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATAI Atai Life Sciences	$2.06 +2.0%	$1.47	$1.03 ▼ $2.57	$412.70M	1.22	1.59 million shs	1.71 million shs
ENTX Entera Bio	$1.95 -0.5%	$1.93	$1.41 ▼ $2.79	$88.63M	1.51	70,814 shs	96,107 shs
RAPP Rapport Therapeutics	$10.82 -2.7%	$10.10	$6.43 ▼ $29.74	$394.91M	N/A	174,806 shs	206,082 shs
URGN UroGen Pharma	$4.19 +2.7%	$10.03	$3.42 ▼ $20.70	$193.19M	0.66	672,612 shs	2.33 million shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATAI Atai Life Sciences	+1.98%	+24.85%	+35.53%	+3.52%	+23.35%
ENTX Entera Bio	-0.96%	-3.94%	-5.80%	-7.14%	-18.07%
RAPP Rapport Therapeutics	-2.70%	+8.63%	-4.92%	-14.67%	+1,081,999,900.00%
URGN UroGen Pharma	+2.70%	-42.68%	-58.92%	-58.43%	-68.52%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATAI Atai Life Sciences	2.3007 of 5 stars	3.7	1.0	0.0	2.5	2.5	0.6
ENTX Entera Bio	1.9241 of 5 stars	3.5	3.0	0.0	2.6	0.8	0.0
RAPP Rapport Therapeutics	1.1103 of 5 stars	3.5	0.0	0.0	0.0	1.7	0.6
URGN UroGen Pharma	3.9837 of 5 stars	4.4	1.0	4.5	2.3	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATAI Atai Life Sciences	3.33	Buy	$8.67	320.71% Upside
ENTX Entera Bio	3.00	Buy	$10.00	412.82% Upside
RAPP Rapport Therapeutics	3.00	Buy	$32.67	201.91% Upside
URGN UroGen Pharma	2.88	Moderate Buy	$27.43	554.62% Upside

Current Analyst Ratings Breakdown

Latest ENTX, RAPP, ATAI, and URGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/23/2025	URGN UroGen Pharma	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $15.00
5/22/2025	URGN UroGen Pharma	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$16.00 ➝ $3.00
5/22/2025	URGN UroGen Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
5/20/2025	ATAI Atai Life Sciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$5.00
5/20/2025	ATAI Atai Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/13/2025	ATAI Atai Life Sciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/13/2025	URGN UroGen Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$55.00 ➝ $55.00
5/8/2025	URGN UroGen Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00
4/29/2025	URGN UroGen Pharma	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/28/2025	URGN UroGen Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00
4/28/2025	URGN UroGen Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$55.00 ➝ $55.00

(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATAI Atai Life Sciences	$1.86M	221.52	N/A	N/A	$1.47 per share	1.40
ENTX Entera Bio	$223K	397.45	N/A	N/A	$0.36 per share	5.42
RAPP Rapport Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
URGN UroGen Pharma	$91.87M	2.10	N/A	N/A	($2.78) per share	-1.51

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATAI Atai Life Sciences	-$40.22M	-$0.91	N/A	N/A	N/A	N/A	-65.75%	-52.71%	8/12/2025 (Estimated)
ENTX Entera Bio	-$8.89M	-$0.26	N/A	N/A	N/A	N/A	-107.24%	-92.29%	8/8/2025 (Estimated)
RAPP Rapport Therapeutics	-$34.79M	-$3.45	N/A	N/A	N/A	N/A	N/A	N/A	6/2/2025 (Estimated)
URGN UroGen Pharma	-$102.24M	-$3.18	N/A	N/A	N/A	-129.11%	N/A	-47.94%	8/12/2025 (Estimated)

Latest ENTX, RAPP, ATAI, and URGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
6/2/2025	Q1 2025	RAPP Rapport Therapeutics	-$0.77	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	ATAI Atai Life Sciences	-$0.19	-$0.15	+$0.04	-$0.15	N/A	$1.56 million
5/12/2025	Q1 2025	URGN UroGen Pharma	-$0.83	-$0.92	-$0.09	-$0.92	$22.71 million	$20.25 million
5/9/2025	Q1 2025	ENTX Entera Bio	-$0.07	-$0.06	+$0.01	-$0.06	N/A	$0.04 million
5/8/2025	Q1 2025	RAPP Rapport Therapeutics	-$0.77	-$0.68	+$0.09	-$0.68	N/A	N/A
3/28/2025	Q4 2024	ENTX Entera Bio	-$0.08	-$0.06	+$0.02	-$0.06	$0.04 million	$0.04 million
3/17/2025	Q4 2024	ATAI Atai Life Sciences	-$0.14	-$0.24	-$0.10	-$0.24	$0.30 million	($0.01) million
3/10/2025	Q4 2024	URGN UroGen Pharma	-$0.69	-$0.80	-$0.11	-$0.80	$25.25 million	$24.57 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATAI Atai Life Sciences	N/A	N/A	N/A	N/A	N/A
ENTX Entera Bio	N/A	N/A	N/A	N/A	N/A
RAPP Rapport Therapeutics	N/A	N/A	N/A	N/A	N/A
URGN UroGen Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATAI Atai Life Sciences	0.14	5.81	5.81
ENTX Entera Bio	N/A	6.61	6.61
RAPP Rapport Therapeutics	N/A	45.91	45.91
URGN UroGen Pharma	4.77	9.00	8.77

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATAI Atai Life Sciences	28.41%
ENTX Entera Bio	14.11%
RAPP Rapport Therapeutics	N/A
URGN UroGen Pharma	91.29%

Insider Ownership

Company	Insider Ownership
ATAI Atai Life Sciences	31.20%
ENTX Entera Bio	10.90%
RAPP Rapport Therapeutics	N/A
URGN UroGen Pharma	5.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATAI Atai Life Sciences	80	200.34 million	115.45 million	Optionable
ENTX Entera Bio	20	45.45 million	31.88 million	Optionable
RAPP Rapport Therapeutics	N/A	36.50 million	N/A	N/A
URGN UroGen Pharma	200	46.11 million	22.26 million	Optionable

ENTX, RAPP, ATAI, and URGN Headlines

Recent News About These Companies

Ongoing Investigation: UroGen Pharma Ltd. (URGN) May Have Misled Shareholders - Levi & Korsinsky Investigates

May 24 at 6:01 PM | accessnewswire.com

UroGen Pharma Ltd. (URGN) Shares Crash Again Amid FDA’s ODAC Vote Against UGN-102, Company Facing Investor Scrutiny – Hagens Berman

May 24 at 4:19 PM | morningstar.com

UroGen Pharma (NASDAQ:URGN) Price Target Cut to $3.00 by Analysts at The Goldman Sachs Group

May 24 at 10:49 AM | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN

May 24 at 9:00 AM | accessnewswire.com

HC Wainwright Reiterates "Neutral" Rating for UroGen Pharma (NASDAQ:URGN)

May 24 at 8:10 AM | marketbeat.com

Kaplan Fox is Investigating Potential Securities Law Violations against UroGen Pharma Ltd. (URGN)

May 23 at 3:41 PM | theglobeandmail.com

Ongoing Securities Investigation into UroGen Pharma Ltd. (URGN) - Contact Levi & Korsinsky

May 23 at 1:00 PM | accessnewswire.com

UroGen Pharma Ltd. (URGN) Shares Crash Again Amid FDA's ODAC Vote Against UGN-102, Company Facing Investor Scrutiny - Hagens Berman

May 23 at 12:30 PM | accessnewswire.com

HC Wainwright & Co. Downgrades UroGen Pharma (URGN)

May 23 at 10:40 AM | msn.com

Potential Securities Fraud: Levi & Korsinsky Investigates UroGen Pharma Ltd. (URGN)

May 23 at 10:15 AM | accessnewswire.com

UroGen Pharma Ltd. (URGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

May 23 at 10:00 AM | accessnewswire.com

Point72 Asset Management L.P. Sells 1,189,532 Shares of UroGen Pharma Ltd. (NASDAQ:URGN)

May 23 at 4:36 AM | marketbeat.com

URGN ACTIVE INVESTIGATION: Lost Money on UroGen Pharma Ltd.? Contact Levi & Korsinsky Now

May 22 at 5:15 PM | accessnewswire.com

UroGen Pharma Ltd. (URGN) Shares Crash Again Amid FDA's ODAC Vote Against UGN-102, Company Facing Investor Scrutiny â€“ Hagens Berman

May 22 at 5:04 PM | globenewswire.com

UroGen tanks as FDA panel vote goes against UGN-102

May 22 at 2:03 PM | thepharmaletter.com

Lost Money on UroGen Pharma Ltd. (URGN)? Contact Levi & Korsinsky About Investigation

May 22 at 10:30 AM | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against UroGen Pharma Ltd. (URGN) and Encourages Stockholders to Learn More About the Investigation

May 22 at 10:00 AM | accessnewswire.com

1,749,142 Shares in UroGen Pharma Ltd. (NASDAQ:URGN) Bought by Toronto Dominion Bank

May 22 at 5:05 AM | marketbeat.com

UroGen Stock Slumps After FDA Advisory Committee Flag Concerns On Its Investigational Drug: But Retail’s Unruffled

May 21 at 10:58 PM | msn.com

What's Going On With UroGen Pharma Stock Wednesday?

May 21 at 5:57 PM | benzinga.com

UroGen crashes as FDA AdCom rebukes bladder cancer drug

May 21 at 5:57 PM | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTX, RAPP, ATAI, and URGN Company Descriptions

Atai Life Sciences NASDAQ:ATAI

$2.06 +0.04 (+1.98%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$2.09 +0.03 (+1.46%)

As of 05/23/2025 07:59 PM Eastern

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Entera Bio NASDAQ:ENTX

$1.93 -0.03 (-1.48%)

As of 05/23/2025 04:00 PM Eastern

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Rapport Therapeutics NASDAQ:RAPP

$10.82 -0.30 (-2.70%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$10.82 0.00 (0.00%)

As of 05/23/2025 04:04 PM Eastern

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.

UroGen Pharma NASDAQ:URGN

$4.19 +0.11 (+2.70%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$4.16 -0.04 (-0.84%)

As of 05/23/2025 07:59 PM Eastern

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time